Association between COVID-19 Infection or Vaccination Outcomes and Methylenetetrahydrofolate Reductase Gene Polymorphism: A Systematic Review of the Literature

• Published in: Journal of personalized medicine 2023-12, Vol.13 (12), p.1687
• Main Authors: Jukic, Ivana, Heffernan, Aisling, Schelling, Alisa Franceska, Kokic Males, Visnja, Savicevic, Nora Josipa, Kovacic, Vedran
• Format: Article
• Language: English
• Subjects: Biomarkers; Clinical outcomes; Clinical trials; Comorbidity; COVID-19; COVID-19 vaccines; Folic acid; Gene polymorphism; Homocysteine; Immunization; Infections; Literature reviews; Methylenetetrahydrofolate reductase; Mortality; Mutation; Pandemics; Patients; Polymorphism; Precision medicine; Risk factors; Severe acute respiratory syndrome coronavirus 2; Systematic review; Tetrahydrofolic acid; Thromboembolism; Thrombosis; Vaccination
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13121687

Thrombosis is a detrimental sequala of COVID-19 infection; thus, prophylactic anti-coagulant therapy has been deemed mandatory in treatment unless serious contraindications are present. Susceptibility to thromboembolic events in COVID-19, or following COVID-19 vaccination, is likely attributable to an interplay of factors, including a patient's baseline clinical status and comorbidities, alongside genetic risk factors. In Europe, 8-20% of the population are homozygous for the MTHFR (methylene tetrahydrofolate reductase) variant, which compromises folate metabolism and elevates homocysteine levels. While heightened homocysteine levels are considered a risk factor for thromboembolic events, the precise clinical significance remains a contentious issue. However, recent research suggests elevated homocysteine levels may predict the course and severity of COVID-19 infection. Given the lack of reliable biomarkers predictive of COVID-19 thrombotic risk existing in practice, and the accessibility of MTHFR screening, we established two main outcomes for this study: (1) to determine the association between hereditary MTHFR mutations and COVID-19 severity and thromboembolic events and (2) to determine the link between MTHFR variants and adverse thrombotic events following COVID-19 vaccination. The review was conducted in accordance with PRISMA guidelines. Medline, Scopus, and Web of Science databases were searched from pandemic inception (11 March 2020) to 30 October 2023. Eligibility criteria were applied, and data extraction performed. From 63 citations identified, a total of 14 articles met the full inclusion criteria (8 of which were cross-sectional or observational studies, and 6 were case studies or reports). Among the eight observational and cross-sectional studies evaluating the relationship between MTHFR variants (C667T; A1298C) and thromboembolic events in COVID-19 infection, four studies established a connection ( = 2200), while the remaining four studies failed to demonstrate any significant association ( = 38). This systematic review demonstrated a possible association between the MTHFR gene variants and COVID-19 severity, thromboembolic events, and adverse events following vaccination. However, the paucity of robust data precluded any firm conclusions being drawn. Further prospective trials are required to determine the connection between the MTHFR gene variant and COVID-19 infection and vaccination outcomes.